Food and Drug Administration’s Position on Commonly Injected Biologic Materials in Orthopaedic Surgery
Authors:
- 26 March 2021
- journal article
- research article
- Published by SAGE Publications in The American Journal of Sports Medicine
- Vol. 49 (12) , 3414-3421
Abstract
The use of biologically based therapies is becoming a popular less-invasive therapy for relieving pain and promoting tissue regeneration. The most commonly used biologics are autologous adipose-derived products, bone marrow aspirations, and platelet-rich plasma (PRP). Birth tissue is a common allogenic source of biologics, including umbilical cord, placental membranes, and amniotic fluid. Injected biologics, depending on the indication and how they are processed, formulated, delivered, and promoted, can be subject to different regulatory pathways. The aim of this review is to provide an overview of these products and procedures and educate the musculoskeletal community about the relevant current Food and Drug Administration (FDA) regulations.Keywords
This publication has 33 references indexed in Scilit:
- Umbilical Cord Tissue Offers the Greatest Number of Harvestable Mesenchymal Stem Cells for Research and Clinical Application: A Literature Review of Different Harvest SitesArthroscopy, 2015
- US Definitions, Current Use, and FDA Stance on Use of Platelet-Rich Plasma in Sports MedicineThe Journal of Knee Surgery, 2014
- Ten Common Questions (and Their Answers) About Off-label Drug UseMayo Clinic Proceedings, 2012
- Platelet-Rich Plasma Differs According to Preparation Method and Human VariabilityJournal of Bone and Joint Surgery, 2012
- Comparison of Growth Factor and Platelet Concentration From Commercial Platelet-Rich Plasma Separation SystemsThe American Journal of Sports Medicine, 2010
- Adipose tissue is an extramedullary reservoir for functional hematopoietic stem and progenitor cellsBlood, 2010
- Off-Label Prescribing: A Call for Heightened Professional and Government OversightJournal of Law, Medicine & Ethics, 2009
- Effect of tissue-harvesting site on yield of stem cells derived from adipose tissue: implications for cell-based therapiesCell and tissue research, 2008
- Off-label Prescribing Among Office-Based PhysiciansArchives of internal medicine (1960), 2006
- The Immunogenicity of Human Adipose‐Derived Cells: Temporal Changes In VitroStem Cells, 2006